

# Cumulative Index 1988

## Volume 6

<b>January</b>	<b>OCCUPATIONAL DERMATOSES</b> , pages 1-159
<b>April</b>	<b>PICMENTATION DISORDERS</b> , pages 161-341
<b>July</b>	<b>DERMATOLOGY IN BLACK PATIENTS</b> , pages 342-496
<b>October</b>	<b>DERMATOLOGIC THERAPY I</b> , pages 497-680

Note: Page numbers of article titles are in **boldface** type.

- Acetylacetone method, to analyze formaldehyde, 99
- Acitretin, for dermatologic conditions, 541
- Acne, and occupational skin diseases, 11
- in black patients, pomades and, 365
  - scarring after, dermabrasion for, 378-380
  - sebaceous gland activity and, 349-351
  - isotretinoin for, 539-540
  - tetracyclines for, 505
  - therapy for, 617
- Acne keloidalis, therapeutic pearl for, 649
- Acne rosacea, metronidazole for, 635
- therapeutic pearls for, 649-650
- Acne vulgaris, antiandrogens for, 635-636
- therapeutic pearls for, 650
- Acquired immune deficiency syndrome. See **AIDS**.
- Acrodermatitis enteropathica, therapy for, 619
- Acropustulosis, of infancy, in black children, 459
- Actinic keratoses, in black patients, 371-372, 374
- interferons for, 572
  - therapeutic pearl for, 664
  - tretinoin plus 5-fluorouracil for, 631
- Actinic reticuloid, in black patients, 374
- Acyclovir, for dermatologic conditions, 527-529
- for herpes genitalis, 454
  - for herpes zoster, 627-628
  - for herpesvirus disorders, 609-610
- AIDS**, ampligen for, 532
- azidothymidine for, 630
  - ganciclovir for, 529-530
  - in black patients, 435-442, 454-455
  - classification of patients, 435
  - clinical features of, 438-441
  - epidemiology of, 435-438
  - Kaposi's sarcoma, 402-403, 440, 454
  - leukoplakia, oral hairy, 455
  - management of, 441
  - inosiplex for, 566-567
  - phosphonoformate for, 530
  - ribavirin for, 526-527
  - therapy for, 611
  - zidovudine for, 531-532
- Air-fluidized beds, for pressure sores, 636-637
- Albinism, 217-228
- clinical features of, 221-223
  - complications of, 225
  - diagnosis of, 225
  - in black patients, 278-279
  - management of, 225-226
  - melanin biosynthesis in, 217-218
  - oculocutaneous, specific types of, 223-225
  - pathogenesis of, 218-219, 221
- Aldrich's disease, pigmentary abnormalities in, 201
- Allergens, contact, physicochemical methods to determine, 97-104
- acidity and alkalinity determinations, 101
  - batch variations in, 103-104
  - chromatography in, 101-103
  - chromium, 98
  - cobalt, 98
  - epoxy resins of bisphenol A type, 99-100
  - formaldehyde, 98-99
  - nickel, 97-98
  - primin, 100-101
  - spectrometry in, 103
  - spectrophotometry in, 103
  - spectroscopy in, 103
- in office workplace, 78
- missed, relevance of, in occupational dermatology, 2-3
- Allergic drug eruptions, retinoids and, 543
- Allergy, and rubber contact urticaria, 50-51
- cutaneous, and occupational skin diseases, 11
  - therapy for, 612-613
  - to protective gloves, for occupational skin diseases, 111-112
- Alopecia**. See also **Hair; Scalp**.
- androgenetic, therapy for, 616
  - in black patients, 388-390
  - hot combing and, 388
  - lipedematous, 393
  - pomades and, 388
  - pseudopelade-like, 393
  - relaxing and waving agents and, 388-389
  - scarring, 393
  - sickle-cell anemia and, 393
  - trauma and, 389-390
  - retinoids and, 543
- Alopecia areata**, cyclosporine for, 580
- hair color changes in, 298
  - inosiplex for, 566
  - therapy for, 616-617, 654

- Amantadine, for dermatologic conditions, 525-526
- Aminopenicillins, for dermatologic conditions, 500-501
- Amoxicillin, for dermatologic conditions, 501
- Ampicillin, for dermatologic conditions, 501
- Ampligen, for dermatologic conditions, 532
- Amyloidosis, macular, friction melanosis and, 323, 325
- Anemia, sickle-cell, and alopecia, in black patients, 393  
cutaneous signs of, in black children, 468-469
- Anesthesia, local, tips for, 662-663
- Annular lesions, in black patients, 360
- Anthralin, for psoriasis, 618
- Antiandrogens, for acne vulgaris, 635-636
- Antibiotics, oral. See *Oral antibiotics*.
- Antibodies, monoclonal, in therapeutic immunomodulation, 564-565
- Antimalarial drugs, and hair color changes, 299  
and hyperpigmentation, 332
- Antiviral chemotherapy, future of, 521-537  
antiquated antivirals, 523-524  
development of nucleoside analogues, 523-524  
new drugs and their testing, 524  
recent work with vidarabine, 524  
licensed and investigational antivirals, 525-533  
acyclovir, 527-529  
amantadine and rimantadine, 525-526  
antiretroviral agents, 532  
disoxaril, 533  
ganciclovir, 529-530  
interferons, 532-533  
phosphonoformate, 530  
ribavirin, 526-527  
zidovudine, 530-532  
pathogenetic and therapeutic considerations, 521-523  
blocking virus attachment, 521-522  
preventing virus entry or replication, 522-523
- Aphthous stomatitis, therapeutic pearl for, 662
- Apocrine glands, structure and function of, in black patients, 345-346
- Arachidonic acid, and its prostaglandin derivatives, effects  
of, on normal and malignant melanocytes, 176-177  
in postinflammatory hyperpigmentation, 187
- Arotinoid ethyl ester, for dermatologic conditions, 541
- Arsenic, exposure to, and hair color changes, 301
- Arthropod bites, therapy for, 620
- Aspirin, and dipyridamole, for atrophie blanche, 614  
interaction of, with pentoxifylline, 594
- Atopic dermatitis, clobazimine for, 582  
essential fatty acids for, 634  
in black children, 467-468
- Atopic eczema, and occupational skin diseases, 10-11
- Atopy, and rubber contact urticaria, 50-51
- Atrophie blanche, therapy for, 614
- Azathioprine, for pemphigus vulgaris, 615
- Azidothymidine, for AIDS, 630
- Bejel, in black patients, 485-486
- Benquin, for depigmentation, in vitiligo, in black patients, 433
- Benoxaprofen, for psoriasis, 619
- Benzathine penicillin G, for syphilis, in black patients, 450
- Black patients, AIDS in. See *AIDS*.  
contact dermatitis in. See *Contact dermatitis*.  
cosmetic surgery in. See *Cosmetic surgery*.  
cutaneous infections in. See *Cutaneous infections*.  
cutaneous reaction patterns in. See *Cutaneous reaction patterns*.  
disorders of hair and scalp in. See *Alopecia; Hair; Scalp*.  
keloids in. See *Keloids*.  
pediatric dermatology in. See *Pediatric dermatology*.  
photosensitivity reactions in. See *Photosensitivity reactions*.  
pigmentary disorders in. See *Pigmentary disorders*.  
pseudofolliculitis barbae in. See *Pseudofolliculitis barbae*.  
requirements for cosmetics for, 489-492  
for hair, 491-492  
for skin, 489-491  
illusion of "natural" products, 492  
sebaceous gland activity in, 349-351  
sebum production data, 349-350  
sexually transmitted diseases in. See *Sexually transmitted diseases*.  
skin cancer in. See *Skin cancer*.  
skin structure and function in, 343-347  
cutaneous appendages, 345-346  
dermis, 344-345  
epidermis, 344  
vitiligo in. See *Vitiligo*.
- Bleomycin, for genital warts, 611
- Bloch-Sulzberger syndrome, clinical features of, 318, 321  
pigmentary abnormalities in, 197-198
- Blood, viscosity of, and pentoxifylline therapy, 585-587
- Bourneville's disease, pigmentary abnormalities in, 198-199
- Bowen's disease, in black patients, 402
- Bullous diseases, therapy for, 615-616
- Bullous pemphigoid, therapeutic pearl for, 665
- Burns, due to hydrofluoric acid, 67-74  
case histories of, 73-74  
chemical and physical properties and uses of acid, 67  
clinical features of, 69  
pathophysiology of, 68-69  
treatment of, 69, 71-73  
calcium gluconate gel, 72  
calcium gluconate injection, 71  
for eye burns, 73  
for inhalation injury, 73  
hyamine or Zephiran soaks, 71  
intra-arterial calcium infusion, 72  
location and size of burn in, 72-73
- Buruli ulcers, in black patients, 483-484
- Café-au-lait spots, in neurofibromatosis, 199  
in tuberous sclerosis, 199
- Calcinosis cutis, pentoxifylline for, 598
- Calcium, intra-arterial infusion of, for hydrofluoric acid burns, 72
- Calcium gluconate, for hydrofluoric acid burns, 71-72
- Calcium-channel blockers, interaction of, with pentoxifylline, 594-595
- Cancer, skin. See *Skin cancer*.
- Candidiasis, AIDS and, in black patients, 455
- Carcinoma, basal cell, in black patients, 371, 374, 392-393, 398-399  
interferons for, 572  
squamous cell, in black patients, 371-372, 374, 399, 401  
interferons for, 572-573
- Casts, peripilar hair, in black patients, 390
- Cefaclor, for dermatologic conditions, 502-503
- Cefadroxil, for dermatologic conditions, 502
- Cellulitis, dissecting, in black patients, 391-392  
of legs, pentoxifylline for, 602
- Cephalexin, for dermatologic conditions, 502
- Cephalosporins, for dermatologic conditions, 502-503
- Cephadrine, for dermatologic conditions, 502

- Cervix, melanosis of, 287
- Chancroid, in black patients, 452
- Cheilitis granulomatosa, therapeutic pearl for, 650
- Chemical peeling, for aging skin, 621-622
- Chemicals, and hyperpigmentation, 327-333  
and hypopigmentation, 333-334  
irritant, and nail disorders, 29  
and occupational skin diseases, 8  
protection of hands against, 105-106, 108-109
- Chemotherapy, antiviral. See *Antiviral chemotherapy*.
- for cancer, and hair color changes, 300  
and hyperpigmentation, 327, 331-332
- Chlamydial infections, in black patients, 451-452
- Chlorpheniramine, plus cimetidine, for urticaria, 634
- Chromatography, to detect contact allergens, 101-103
- Chromium, physicochemical methods to detect, 98
- Chromotropic acid method, to analyze formaldehyde, 98
- Ciclopirox olamine, for fungal infections, 611
- Cimetidine, chlorpheniramine plus, for urticaria, 634  
for herpes simplex, 629-630  
for herpesvirus disorders, 610
- Ciprofloxacin, for dermatologic conditions, 514-515
- Circumscribed dermal melanoses, 315-326  
acquired bilateral nevus of Ota-like macules, 321  
blue macules associated with progressive systemic scleroderma, 321, 323  
blue nevus, 316  
friction melanosis and macular amyloidosis, 323, 325  
incontinentia pigmenti, 318, 321  
nevus of Ito, 318  
nevus of Ota, 316, 318  
sacral blue (mongolian) spots, 315-316  
treatment of, 325
- Clindamycin, for dermatologic conditions, 508-509
- Clobetasol propionate, side effects of, 645-646  
hypothalamic-pituitary-adrenal suppression, 646  
use and abuse of, 643-647  
after cryotherapy, 645  
for atypical pyogenic granuloma, 645  
for discoid lupus erythematosus, 644  
for eczema, 644  
for granuloma annulare, 645  
for lichen planus, 644-645  
for lichen sclerosis et atrophicus, 645  
for pemphigus and cicatricial pemphigoid, 645  
for psoriasis, 643-644  
for vitiligo, 645
- Clofazimine, for dermatologic conditions, 580-583  
mode of action and dosage of, 581-582  
pharmacology of, 581  
toxicity of, 581
- Clonidine, transdermal, allergic reactions to, in black patients, 366
- Cobalt, physicochemical methods to detect, 98
- Colchicine, myopathy and neuropathy due to, 637
- Collagen synthesis, and keloid formation, in black patients, 418-419
- Collagen-vascular diseases, therapy for, 613-615
- Colony-stimulating factors, in therapeutic immunomodulation, 564
- Condylomata acuminata, interferons for, 532-533, 570-571  
therapy for, 610-611
- Conjunctiva, acquired melanosis of, 290
- Contact dermatitis, in black patients, 363-367  
epidemiology of cutaneous reactivity, 364  
in response to drugs, 366  
in vitro percutaneous absorption, 365-366  
in vivo percutaneous absorption, 366  
irritant reactions, 364  
physiologic differences in barrier function, 363-364  
pomade acne, 365  
sensitization, 365  
subjective (sensory) irritation, 364
- Cornification, disorders of, isotretinoin for, 540
- Coronary heart disease, retinoids and, 547
- Corticosteroids, and postinflammatory hyperpigmentation, 189  
for herpesvirus disorders, 610  
for keloids, in black patients, 420  
for postinflammatory hyperpigmentation, 190-191  
therapeutic pearls and, 655-656
- Cosmetic dermatology, for aging skin, 621-622
- Cosmetic surgery, in black patients, 377-386  
dermabrasion, 378-380  
nose, lip, and chin complex, 383-384  
scar correction, 380-383  
surgical hair replacement, 378
- Cradle cap, in black children, 460
- Craven's test, to detect primum, 100
- Cryoglobulinemia, pentoxifylline for, 600
- Cryosurgery, for dermatofibroma, 632  
for skin cancer, sensory loss after, 631-632
- Cryotherapy, clobetasol propionate after, 645  
for genital warts, 611
- Cutaneous infections, in black patients, 475-488  
bacterial, 475-479  
dermatitis cruris pustulosa et atrophica, 478  
dermatitis papillaris capillitii, 410-411, 478-479  
diphtherial skin infections, 477-478  
impetigo, 476  
syphilis, 477  
factors predisposing to, 475  
fungal, 479-482  
tinea capitis, 480-482  
tinea versicolor, 479-480  
mycobacterial, 482-484  
leprosy, 482-483  
*Mycobacterium ulcerans*, 483-484  
tuberculosis of skin, 483  
treponemal, 484-486  
endemic syphilis, 485-486  
pinta, 485  
yaws, 484-485  
mupirocin for, 627
- Cutaneous reaction patterns, in black patients, 353-362  
annular lesions, 360  
follicular or papular reactions, 359-360  
granulomatous or fibromatous lesions, 360  
pigmentary disorders, 354-359  
hyperpigmentation, 355, 358-359  
hypopigmentation, 354-355  
ulcerative lesions, 360-361  
vesicobullous lesions, 360
- Cyclophosphamide, risk of malignancy with, 637-638
- Cyclosporine, for dermatologic conditions, 575-580  
actions and uses of, 577  
for psoriasis, 577-579, 619  
for Sézary syndrome, 579  
mode of action of, 576  
pharmacology of, 575-576  
toxicity of, 576-577  
interaction of, with ketoconazole, 612
- Dapsone, for granuloma annulare, 619  
for leukocytoclastic vasculitis, 614  
for lupus erythematosus, 613, 614  
for pemphigus foliaceus, 615  
substitute for, 656

- Deafness, congenital sensorineural, pigmentary abnormalities and, 213-214  
     in Waardenburg's syndrome, 211  
     with piebaldism, 213
- Deoxyacyclovir, for herpesvirus disorders, 610
- Depigmentation, for vitiligo, in black patients, 431
- Depilatories, chemical, for pseudofolliculitis barbae, in black patients, 409
- Dermabrasion, for acne scars, in black patients, 378-380
- Dermatitis, atopic, therapeutic pearls for, 650-651  
     chronic, of hands, PUVA and UVB therapy for, 635  
     diaper, therapeutic pearls for, 652  
     exfoliative, therapeutic pearl for, 651  
     in black adults, contact. See *Contact dermatitis*.  
         seborrheic, 394  
             AIDS and, 440  
         in black children, atopic, 467-469  
             diaper, 460-461  
             seborrheic, 460  
         otitis externa, therapeutic pearls for, 652  
         rhus, therapeutic pearls for, 652-653  
         seborrheic, therapeutic pearls for, 653  
         therapy for, atopic, 613  
             clofazimine, 582  
             essential fatty acids, 634  
             nonatopic, 613  
             seborrheic, 612-613
- Dermatitis cruris pustulosa et atrophica, in black patients, 478
- Dermatitis herpetiformis, therapy for, 616
- Dermatitis papillaris capillitii, in black patients, 410-411, 478-479
- Dermatofibromas, cryosurgery for, 632  
     therapy for, 620
- Dermatofibrosarcoma protuberans, in black patients, 403
- Dermatomyositis, therapy for, 614
- Dermatophytoses. See *Cutaneous infections, fungal*.
- Dermatoses, in black children. See *Pediatric dermatology*.  
     occupational. See *Occupational dermatoses*.  
     pseudo-occupational, 3  
     subcorneal pustular, etretinate for, 639
- Diabetes mellitus, complications of, pentoxifylline for. See *Pentoxifylline*.
- Diaper dermatitis, in black children, 460-461
- Dicloxacillin, for dermatologic conditions, 500
- Dinitrochlorobenzene, for genital warts, 611
- Diphtheria, cutaneous, in black patients, 477-478
- Dipyridamole, interaction of, with pentoxifylline, 594
- Disoxaril, for dermatologic conditions, 533
- Dissecting cellulitis of scalp, therapeutic pearl for, 650
- Disulfiram, for nonatopic dermatitis, 613
- Dyskeratosis congenita, pigmentary abnormalities in, 196-197
- Dystopia canthorum, in Waardenburg's syndrome, 211
- Ear piercing, tips for, 663
- Eczema, chronic, of hands, grenz ray therapy for, 635  
     clobetasol propionate for, 644  
     nummular, therapeutic pearl for, 652  
     post-traumatic, 35-42  
         clinical classification of, 35-39  
         idiopathic reaction, 38-39  
         isomorphic reaction, 35-36  
         differential diagnosis of, 39  
         therapeutic pearls for, 650-652  
         therapy for, 612-613
- Epiloia, pigmentary abnormalities in, 198-199
- Epoxy resins of bisphenol A type, physicochemical methods to detect, 99-100
- Erythema nodosum, therapy for, 615
- Erythema toxicum neonatorum, in black children, 459
- Erythromycin, for dermatologic conditions, 507
- Essential fatty acids, for atopic dermatitis, 634
- Etretin, for psoriasis, 639-640
- Etretinate, and skeletal muscle damage, 641  
     and skeletal toxicity, relation between, 640-641  
     for cutaneous T-cell lymphomas, 638-639  
     for dermatologic conditions, 553-560  
         clinical use of, 557-559  
         dosage and administration of, 555  
         mode of actions of, 555  
         pharmacology of, 553-554  
         side effects of, 555-557  
         teratogenicity of, 554-555  
     for epithelial neoplasms, 620  
     for extensive warts, in children, 639  
     for psoriasis, 540, 618-619  
     for subcorneal pustular dermatosis, 639  
     hepatotoxicity of, 641  
     PUVA plus, for psoriasis, 640
- Eyes, hydrofluoric acid burns of, treatment of, 73  
     toxicities of, retinoids and, 543-544
- Fasciitis, eosinophilic, pentoxifylline for, 598, 600
- Fibrinogen, and pentoxifylline therapy, 593
- Fibromatous lesions, in black patients, 360
- Fibronectin, and keloid formation, in black patients, 418
- Fisch's syndrome, depigmentation in, 212
- Fluorobutyrophenone, and hair color changes, 300
- 5-Fluorouracil, for epithelial neoplasms, 620  
     for vitiligo, 617  
     tretinoin plus, for actinic keratoses, 631
- Follicular reactions, in black patients, 359-360
- Formaldehyde, physicochemical methods to detect, 98-99
- Fovea, development of, in albinism, 222
- Fox-Fordyce disease, in black patients, 359
- Freckling, axillary, in neurofibromatosis, 199-200
- Fundus, pigmentation of, in albinism, 222
- Fungal infections, therapy for, 611-612
- Furocoumarins, and hyperpigmentation, 333
- Futcher's lines, in hyperpigmentation, in black patients, 355, 358
- Ganciclovir, for dermatologic conditions, 529-530
- Genetic disorders, photosensitivity and, in black patients, 374  
     pigmentary abnormalities in, 193-203  
         Albright's polyostotic fibrous dysplasia, 201  
         dyskeratosis congenita, 196-197  
         incontinentia pigmenti, 197-198  
         LEOPARD syndrome, 193  
         NAME and LAMB syndromes, 193, 196  
         neurofibromatosis, 199-201  
         Peutz-Jeghers syndrome, 196  
         tuberous sclerosis, 198-199
- Genital herpes, inosine pranobex for, 628-629
- Genital warts, in black patients, 453  
     therapy for, 610-611
- Genitalia, melanosis of, 287, 290
- Glans penis, macular hyperpigmentation of, 290
- Glomerulonephritis, poststreptococcal, impetigo and, in black patients, 476
- Gloves, rubber. See *Rubber gloves*.
- Goeckerman regimen, for psoriasis, 618
- Gonorrhea, in black patients, 450-451

- Granuloma annulare, clobetasol propionate for, 645  
therapy for, 619, 653
- Granuloma inguinale, in black patients, 452-453
- Granulomata, atypical pyogenic, clobetasol propionate for, 645  
necrobiotic, pentoxifylline for, 596, 598
- Granulomatous lesions, in black patients, 360
- Grenz ray therapy, for chronic hand eczema, 635
- Griseofulvin, for fungal infections, 611-612  
plus tioconazole, for onychomycosis, 630-631
- Grotthus-Draper law, in photobiologic events, 370
- Hailey-Hailey disease, clobetasol propionate for, 645  
therapy for, 615
- Hair. *See also Alopecia; Scalp.*  
diseases of, therapy for, 616-617, 653-654  
melanocytes of, 168-171  
structure of, in black patients, 387
- Hair color, changes in, 295-303  
acquired progressive kinking, 298  
arsenic exposure and, 301  
drug-induced, 299-300  
graying, 295-296  
green hair, 300-301  
in alopecia areata, 298  
nutritional and metabolic disorders and, 298-299  
postinflammatory darkening, 296, 298
- Hair relaxing and waving agents, and alopecia, in black patients, 388-389
- Hair replacement, surgical, in black patients, 378
- Hair shaft, abnormalities of, in black patients, 391
- Hamartomatosis, pigmentary abnormalities in, 198-199
- Hand-foot syndrome, in sickle-cell anemia, in black children, 469
- Hands, chronic dermatitis of, PUVA and UVB therapy for, 635  
chronic eczema of, Grenz ray therapy for, 635  
occupational dermatitis of, prevention of, 88-89  
occupational dermatoses of, 105-114  
analysis of hazards in, 105-106  
barrier creams in, 113  
protective gloves in. *See Rubber gloves.*
- Hansen's disease, clofazimine for, 581  
in black patients, 482-483
- Hemangioma, therapeutic pearl for, 663-664
- Hemorrhoids, therapeutic pearl for, 654
- Heparin, for atrophie blanche, 614
- Hermansky-Pudlak syndrome, clinical features of, 224
- Herpes, genital, acyclovir for, 527-529  
in black patients, 453-454  
inosine pranobex for, 629-629
- Herpes simplex, cimetidine for, 629-630  
L-lysine for, 629
- Herpes zoster, acyclovir for, 627-628
- Herpesvirus disorders, therapy for, 609-610
- Heterochromia irides, in Waardenburg's syndrome, 211  
piebaldism and, 210
- Hidradenitis suppurativa, therapeutic pearl for, 650
- Hirschsprung's disease, piebaldism and Waardenburg's syndrome with, 212-213
- Hirsutism, therapy for, 616
- Hormones, and hyperpigmentation, 332  
steroid, effects of, on pigment cells, 178-180
- Human immunodeficiency virus (HIV), and AIDS, in black patients, 435, 454-455
- Human papillomavirus infections, in black patients, 453
- Hyamine soaks, for hydrofluoric acid burns, 71
- Hydrofluoric acid, burns due to. *See Burns.*
- Hydroquinone, and ochronosis, in black patients, 276-278  
for melasma, 617  
for postinflammatory hyperpigmentation, 190-191  
for vitiligo, 236  
monobenzyloether of, and hypopigmentation, 333-334
- Hydroxychloroquine, for dermatomyositis, 614
- Hyperhidrosis, palmoplantar, iontophoresis for, 637  
therapy for, 617
- Hyperlipidemia, retinoids and, 546-547
- Hyperpigmentation, chemical and pharmacologic agents and, 327-333  
disorders of, in black patients. *See Pigmentary disorders.*  
postinflammatory, 185-192  
biologic significance of, 185-186  
mediators affecting, 186-189  
arachidonic acid and prostaglandins, 187  
corticosteroids, 189  
interferon, 189  
peptides, 187-188  
urticaria pigmentosa, 189  
pigment cell involvement in, 189-190  
treatment of, 190-191
- Hyperplasia, sebaceous, therapeutic pearl for, 664
- Hypersensitivity reactions, cyclosporine for, 580
- Hypertriglyceridemia, retinoids and, 547
- Hypomelanosis, idiopathic guttate. *See Idiopathic guttate hypomelanosis.*
- Hypopigmentation, chemical and pharmacologic agents and, 333-334  
disorders of, in black patients. *See Pigmentary disorders.*
- Hypothalamic-pituitary-adrenal suppression, clobetasol propionate and, 646
- Ichthyosis, therapy for, 619
- Idiopathic guttate hypomelanosis, 241-247  
clinical features of, 244-245  
etiology and pathogenesis of, 241  
genetic considerations in, 241-244  
actinic influence, 242  
exchange grafts, 242-243  
historical background of, 241  
in black patients, 278  
pathologic findings in, 245-246  
treatment of, 246-247
- Immunomodulation, therapeutic, 561-568  
colony-stimulating factors, 564  
interferons, 563-564  
interleukins, 561-563  
monoclonal antibodies, 564-565  
synthetic immunomodulators, 565-567
- Impetigo, etiology and therapy of, 627  
in black patients, 476
- Incontinentia pigmenti, clinical features of, 318, 321  
pigmentary abnormalities in, 197-198
- Infections, cutaneous. *See Cutaneous infections.*  
fungal, therapy for, 611-612  
of nails, occupational, 28-29
- Infundibulocystitis, in black patients, 359
- Inhalation injury, hydrofluoric acid in, treatment of, 73
- Inks, used in printing industry, and dermatitis, 63-64, 85
- Inosine pranobex, for genital herpes, 628-629
- Inosiplex, for alopecia areata, 617  
in therapeutic immunomodulation, 565-567
- Insulin, in vitro effects of, on melanocyte function and proliferation, 180

- Integumental pigmentation, endocrine factors and, 175-183  
  arachidonic acid and prostaglandin derivatives, and normal and malignant melanocytes, 176-177  
  in vitro effects of insulin on melanocyte function and proliferation, 180  
  response of melanocytes to ultraviolet radiation, 176  
  response of normal and malignant melanocytes to melanocyte-stimulating hormone, 177-178  
  steroid hormones and pigment cells, 178-180  
Interferons, and postinflammatory hyperpigmentation, 189  
  for dermatologic conditions, 532-533, 569-574  
  chemistry and production of, 569-570  
  clinical use of, 570-571  
  mode of actions of, 570  
  trials of, 571-574  
  for genital warts, 611  
  for psoriasis, 618  
  in therapeutic immunomodulation, 563-564  
Interleukins, in therapeutic immunomodulation, 561-563  
Intertrigo, therapeutic pearls for, 652  
Iontophoresis, for palmoplantar hyperhidrosis, 637  
Iris, pigmentation of, in albinism, 222  
  pigmented raised nodules of, in neurofibromatosis, 200  
Isotretinoin, and teratogenicity, 548  
  for acne and related conditions, 539-540  
  for cutaneous T-cell lymphomas, 638-639  
  for disorders of cornification, 540  
  for epithelial neoplasms, 620, 621  
  for lichenoid diseases, 619  
  for lupus erythematosus, 614  
  for rosacea, 617  
  therapeutic pearls and, 656  
  
Kaposi's sarcoma, AIDS and, in black patients, 402-403, 440, 454  
  interferons for, 563, 573  
  therapy for, 621  
Kawasaki disease, therapy for, 615  
Keloids, in black patients, 360, 413-424  
  clinical features of, 416-417  
  differential diagnosis of, 419  
  epidemiology of, 414  
  etiology of, 414-416  
  historical perspective on, 413  
  pathogenesis of, 418-419  
  pathology of, 417-418  
  therapy for, 380-383, 419-422  
    pressure, 421  
    radiation, 421  
    steroid injections, 420  
    surgery, 420-421  
  pentoxifylline for, 602  
  therapy for, 620  
Kenalog-10, for keloids, in black patients, 420  
Ketoconazole, for fungal infections, 611-612  
  for pityriasis versicolor, 631  
  interaction of, with cyclosporine, 612  
  therapeutic pearls and, 656-657  
Klein's syndrome, depigmentation in, 212  
Koebner reaction, in post-traumatic eczema, 35-36  
Koilonychia, occupational, 2  
Kyrle's disease, in black patients, 359  
  
penicillins, 497, 499-502  
  adverse reactions to, 501-502  
  available drugs and their properties, 497, 499-501  
  structure and actions of, 497  
LAMB syndrome, pigmentary abnormalities in, 193, 196  
Laser therapy, for keloids, in black patients, 422  
Legs, cellulitis of, pentoxifylline for, 602  
  chronic ulcers of, ultrasonography for, 636  
  ulcers of, pentoxifylline for, 600  
LEOPARD syndrome, pigmentary abnormalities in, 193  
Leprosy, clofazimine for, 581  
  in black patients, 482-483  
Leukoderma, in black patients, 354-355  
Leukoedema, in black patients, 354-355  
Leukonychia, of nails, clinical features of, 305-310  
Leukoplakia, in dyskeratosis congenita, 197  
  oral hairy, and AIDS, in black patients, 455  
Lice, therapy for, 612  
Lichen nitidus, in black children, 462-463  
Lichen planus, clobetasol propionate for, 644-645  
  therapy for, 619, 654-655  
Lichen sclerosis, etretinate for, 558-559  
Lichen sclerosus et atrophicus, clobetasol propionate for, 645  
Lichen spinulosus, in black children, 463  
Lichen striatus, in black children, 463  
Lichen urticatus, in black children, 463-464  
Livedo vasculitis, pentoxifylline for, 602, 665  
Liver, damage to, methotrexate and, screening for, 641-642  
  toxicities of, retinoids and, 546  
Lubricants, therapeutic pearls and, 657  
Lupus erythematosus, discoid, clobetasol propionate for, 644  
  clofazimine for, 582  
  cyclosporine for, 580  
  etretinate for, 558  
  in black patients, 373-374  
  therapy for, 613-614, 655  
Lymphedema, pentoxifylline for, 602  
Lymphocytoma cutis, therapeutic pearl for, 655  
Lymphogranuloma venereum, in black patients, 452  
Lymphomas, cutaneous T-cell, etretinate for, 558  
  extracorporeal photochemotherapy for, 638  
  interferons for, 573  
  isotretinoin and etretinate for, 638-639  
Lymphoproliferative disorders, therapy for, 621  
L-Lysine, for herpes simplex, 629  
  
Macrolides, for dermatologic conditions, 506-508  
  adverse reactions to, 507-508  
  available drugs and their properties, 506-507  
  structure and actions of, 506  
Macular pigmentation, of palms and soles, in black patients, 358  
Mastocytosis, therapy for, 621  
McCune-Albright's disease, pigmentary abnormalities in, 201  
Meat tenderizers, for arthropod bites, 620  
Meclorethamine, for mycosis fungoides, 621  
Meclofenamate, for psoriasis, 619  
Medicolegal aspects, of occupational dermatoses. *See Occupational dermatoses.*  
Mee's lines, of nail matrix, 310  
Melanin, biosynthesis of, in albinism, 217-218  
Melanoacanthoma, clinical features of, 286  
Melanocytes, function and proliferation of, in vitro effects of insulin on, 180



- in pigmentation disorders, 161-173
  - establishment of, 161-163
  - in hair, 168-171
  - melanosomal transfer, 163-164
  - melanosome translocation, 164-165
  - pigment synthesis, 165-168
- normal and malignant, effects of arachidonic acid and its prostaglandin derivatives on, 176-177
- response of, to melanocyte-stimulating hormone, 177-178
  - to ultraviolet radiation, 176
- Melanoma, malignant, in black patients, 371, 374, 401-402
  - interferons for, 573
  - melanocytic nevi and. See *Nevi*.
  - therapy for, 620
- of nails, 311
- pentoxifylline for, 602, 604
- vittiligo and, 234
- Melanosis, circumscribed dermal. See *Circumscribed dermal melanoses*.
- friction, and macular amyloidosis, 323, 325
- mucosal, 283-293
  - conjunctival, 290
  - genital, 287, 290
  - oral, 283-287
    - differential diagnosis of, 285-286
  - volar macules, 290, 292
- transient neonatal pustular, in black children, 457, 459
  - in black patients, 276
- Melasma, in black patients, 358
  - therapy for, 617
- Mephensin, and hair color changes, 300
- Methotrexate, for keloids, in black patients, 422
  - for psoriasis, and liver damage, screening for, 641-642
  - for rheumatoid ulcerations, 614
- Methoxsalen, for vitiligo, in black patients, 430-431
- Metronidazole, for acne rosacea, 635
  - for dermatologic conditions, 513-514
- Miconazole, and hydrocortisone, for seborrheic dermatitis, 612
- Miliaria, in black children, 460
- Minoxidil, and hair color changes, 300
  - for androgenetic alopecia, 616
- Mirowsky phenomenon, in black patients, 371
- Molluscum contagiosum, in black patients, 455
  - therapeutic pearls for, 657
- Mongolian spots, clinical features of, 315-316
  - in black children, 460
  - in black patients, 273, 275
- Monobenzyl ether of hydroquinone cream, for depigmentation, in vitiligo, in black patients, 433
- Monoclonal antibodies, in therapeutic immunomodulation, 564-565
- Morphea, linear, D-penicillamine for, 632
  - pentoxifylline for, 600
  - therapeutic pearl for, 657
- Mouth, pigmentation of, in black patients, 358
- Mucosae, melanosis of. See *Melanosis*.
- Muehrcke's lines, of nail bed, 310-311
- Multiple lentiginos syndromes, pigmentary abnormalities in, 193, 196
- Mupirocin, for skin infections, 627
- Musculoskeletal system, toxicities of, retinoids and, 544-545
- Mycobacterium ulcerans*, in black patients, 483-484
- Mycosis fungoides, in black patients, 403
  - interferons for, 573
  - therapy for, 621
- Myopathy, and neuropathy, colchicine, 637
- Myxedema, pentoxifylline for, 602
- Nails, changes in, retinoids and, 543
  - dystrophy of, in dyskeratosis congenita, 197
- occupational disorders of, 27-33
  - diseases due to chemicals, 29
  - function and anatomy in, 27-28
  - infectious diseases, 28-29
  - traumatic, 29, 32
- pigmentary abnormalities of, 305-313
  - leukonychia, 305-310
  - Mee's lines, 310
  - melanoma, 311
  - Muehrcke's lines, 310-311
  - pigmentation of, in black patients, 358
  - therapeutic pearls for, 659
- NAME syndrome, pigmentary abnormalities in, 193, 196
- Necrobiosis lipoidica, therapeutic pearls for, 659
- Neoplastic diseases, therapy for, 620-621
- Nephropathy, diabetic, pentoxifylline for, 596
- Nettleship-Falls ocular albinism, clinical features of, 224-225
- Neuralgia, postherpetic, systemic steroids for, 628
- Neurofibromatosis, pigmentary abnormalities in, 199-201
- Neuropathy, and myopathy, colchicine, 637
- Nevi, acquired bilateral, of Ota-like macules, clinical features of, 321
  - acquired melanocytic, and malignant melanoma, 250-251
  - blue, clinical features of, 316
  - clinical and histologic features of, 133-156
  - common, 258-259
  - congenital, and malignant melanoma, 254-255
  - dysplastic, 257-269
    - and familial melanoma, 260-262
    - and malignant melanoma, 251, 253-254
    - and radial growth-phase melanoma, 265, 267
    - and sporadic melanoma, 262
    - and vertical growth-phase melanoma, 267-268
    - as potential precursors for melanoma, 260
    - as risk marker for melanoma, 260
    - in dysplastic nevus syndromes, 263
    - in persons with no history of melanoma, 262-263
    - management of, 263-265
    - melanocytes in, 257-258
    - morphology of, 259-260
  - melanocytic, and malignant melanoma, 249-256
    - terminology for, 250
  - nevocellular, therapeutic pearl for, 664
  - of Ito, clinical features of, 318
  - of Ota, clinical features of, 316, 318
- Nickel, physicochemical methods to detect, 97-98
- Nifedipine, for Raynaud's phenomenon, 614, 632-633
- Nitro compounds, and hyperpigmentation, 332
- Norfloracin, for dermatologic conditions, 514-515
- Nummular eczema, therapeutic pearl for, 652
- Nystagmus, in albinism, 221-222
- Nystatin, for fungal infections, 612
- Occupational dermatoses, allergic contact, protective gloves for, 118
  - analyzing workplace, 1-5
  - incidental effects, 3-4
  - initiation of research, 3
  - irritant contact dermatitis, 1-2, 57-58
    - protective gloves for, 117-118
  - minor dermatoses, 2
  - missed allergens, 2-3
  - pseudo-occupational dermatoses, 3
  - psychic possession, 3
  - relevance of positive patch tests, 2

## Occupational dermatoses (Continued)

- atopic, prevention of, 87-88
- contact, sources of information on, 16
- frequency of, 122
- from paper, in office workers, 77-78
- in office, 75-79
  - allergens in, 78
  - epidemic psychogenic illness, 75
  - paper dermatitis, 77-78
  - sick-building syndrome, 75-76
  - visual display terminals and, 76-77, 81-85
    - clinical examination of referred cases, 83
    - epidemiologic studies of, 82
    - ongoing and planned studies of, 84
    - studies in patients with rosacea, 82-83
- in printing industry, 61-66
  - contactants in, 65
  - diagnosis of, 65-66
  - extent of exposure in, 65
  - technology in, 61-64
- in rubber manufacturing industries, 53-59
  - allergic contact, 56-57
  - chemistry in, 53-54
  - irritant contact, 57-58
  - prevention of, 58
  - processes used in, 54-56
- irritant, 1-2, 57-58
  - protective gloves for, 117-118
- medicolegal aspects of, 121-127
  - ability to compete in open labor market, 124
  - adjudication proceedings, 122-123
  - case studies, 125-127
  - dermatologic examination, 124-125
  - impairment and disability, 123-124
  - medical reports, 123, 125
  - workers' compensation insurance, 123
  - workers' compensation laws, 122
- minor, 2
- of hand, patch testing for. See *Patch tests*.
- prevention of, 88-89
- predisposing factors in, 7-13
  - host-related, 9-12
  - indirect, 12
  - job-related, 7-9
- prevention of, 87-96
  - environmental safety measures in, 91-92
    - example of approach to, 94-95
    - health care referral system in, 91
    - personal safety measures in, 92-94
    - pre-employment examination in, 87-89
    - worker education and monitoring in, 89-91
  - protection of hands against. See *Rubber gloves*.
  - right-to-know laws and, 21-26
    - access to trade secret information, 22-23
    - federal hazard communication standard, 21-22
    - material data safety sheets, 22, 23, 26
    - state and local legislation, 22
- sources of information for, 15-19
  - computerized database, 18-19
  - contact dermatitis, 16
  - identity of toxic substances, 17-18
  - industrial hygiene, 17
  - occupational dermatology, 15-16
  - occupational medicine, 16-17
  - rehabilitation, 19
  - technique for research on, 4-5
- Ochronosis, hydroquinone-induced, in black patients, 276-278
- Onycholysis, occupational, 2
- Onychomycosis, griseofulvin plus tioconazole for, 630-631
  - therapeutic pearls for, 658

- Oral antibiotics, for dermatologic conditions, 497-520
  - clindamycin, 509-509
  - $\beta$ -lactams. See  *$\beta$ -Lactams*.
  - macrolides. See *Macrolides*.
  - metronidazole, 513-514
  - quinolones. See *Quinolones*.
  - rifampin, 511-513
  - tetracyclines. See *Tetracyclines*.
  - trimethoprim-sulfamethoxazole. See *Trimethoprim-sulfamethoxazole*.

- Osteopathia striata, white forelock and, 210
- Ostomy care, tips for, 663
- Otitis externa dermatitis, therapeutic pearls for, 652
- Oxsoresalen, for vitiligo, in black patients, 430-433

- Palmoplantar hyperhidrosis, iontophoresis for, 637
- Palmoplantar papulopustular lesions, retinoids and, 543
- Palmoplantar pustulosis, clofazimine for, 582
  - therapeutic pearl for, 661
- Panencephalitis, subacute sclerosing, inosiplex for, 565-566
- Papain, for arthropod bites, 620
- Papanicolaou smears, for genital warts, 453
- Papular reactions, in black patients, 359-360
- Papulosis, lymphomatoid, therapy for, 621
- Para-aminobenzoic acid, and hair color changes, 300
- Parasitosis, delusions of, therapeutic pearl for, 650
- Paronychia, therapeutic pearl for, 658
- Patch tests, in occupational hand dermatitis, 43-46
  - actions when test is negative, 45-46
  - actions when test is positive, 45
  - determination of appropriate test in, 44-45
  - determination of exposure in, 43-44
  - in printers, 65-66
  - indications for, 43
  - positive, relevance of, in occupational dermatology, 2
  - to detect primin, 100-101
- Pediatric dermatology, in black patients, 457-473
  - atopic dermatitis, 467-469
  - childhood infections, 461-462
  - cutaneous signs of sickle-cell anemia, 469
  - lichen nitidus, 463
  - lichen spinulosus, 463-464
  - lichen striatus, 463
  - neonatal dermatoses, 457, 459-461
    - acropustulosis of infancy, 459
    - diaper dermatitis, 460-461
    - erythema toxicum neonatorum, 459
    - miliaria, 460
    - mongolian spots, 460
    - seborrheic dermatitis, 460
    - transient neonatal pustular melanosis, 457, 459
  - papular urticaria, 464
  - pediculosis capitis, 462
  - pityriasis alba, 466-467
  - pityriasis lichenoides chronica, 465
  - psoriasis, 465-466
  - scabies, 462
  - urticaria pigmentosa, 464-465
- Pediculosis, of eyelashes, therapeutic pearl for, 658-659
- Pediculosis capitis, in black children, 462
- Pemphigoid, bullous, therapy for, 615
- Pemphigus, benign chronic familial, therapy for, 615, 665
- Pemphigus erythematosis, clobetasol propionate for, 645
- Pemphigus foliaceus, clobetasol propionate for, 645
  - therapy for, 615
- Pemphigus vulgaris, therapy for, 615, 666
- D-Penicillamine, for linear morphea, 632
- Penicillins, for dermatologic conditions. See  *$\beta$ -Lactams*.



- Penis, melanosis of, 287
- Pentoxifylline, for dermatologic conditions, 585-608
- blood hyperviscosity and, 587-588
  - blood viscosity and, 585-587
  - calcinosis cutis, 598
  - cellulitis of leg, 602
  - complications of diabetes mellitus, 595-596, 598
    - diabetic necrobiotic granulomata, 596
    - eruptive xanthomata, 596, 598
    - nondiabetic necrobiotic granulomata, 598
    - retinopathy and nephropathy, 596
    - trophic ulcers, 595-596
  - cryoglobulinemia, 600
  - drug interactions with, 593-595
    - aspirin, 594
    - calcium-channel blockers, 594-595
    - dipyridamole, 594
    - warfarin, 593-594
  - eosinophilic fasciitis, 598, 600
  - fibrinogen and, 593
  - keloids, 602
  - leg ulcers, 600
  - livedo vasculitis, 602
  - lymphedema and myxedema, 602
  - melanoma, 602, 604
  - morphea, 600
  - pharmacology of, 588-589
  - plasma viscosity and, 593
  - platelets and, 591-593
  - pyoderma gangrenosum, 600, 602
  - Raynaud's phenomenon, 598
  - red blood cells and, 589-590
  - scleroderma, 598
  - surgical usage, 602
  - vasculitis, 600
  - white blood cells and, 590-591
- Peptide mediators, in postinflammatory hyperpigmentation, 187-188
- Perifolliculitis capitis abscedens et suffodiens, in black patients, 391-392
- Peutz-Jeghers syndrome, pigmentary abnormalities in, 196
- Phenothiazines, and hyperpigmentation, 332
- Phosphonofornate, for dermatologic conditions, 530
- Photoallergy, in black patients, 373
- Photochemotherapy, extracorporeal, for cutaneous T-cell lymphomas, 638
- for mastocytosis, 621
- Photophobia, in albinism, 221
- Photosensitivity reactions, in black patients, 369-375
- classification and distribution of, 370
  - direct disorders, 370-372
  - indirect disorders, 372-373
  - of endogenous origin, 373-374
    - actinic reticuloid, 374
    - genetic disorders, 374
    - polymorphic light eruption, 374
    - solar urticaria, 374
  - photobiologic events, 370
  - physical and environmental factors in, 369-370
- Phototherapy, plus etretinate, for dermatologic conditions, 557
- Piebaldism, and heterochromia irides, 210
- and Waardenburg's syndrome, with Hirschsprung's disease, 212-213
  - animal models of, 207, 209
  - clinical features of, 206-207
  - differential diagnosis of, 209
  - embryology of melanin pigmentary system in, 205-206
  - histology of, 207
  - incidence and heredity of, 206
  - isolated white forelock in, 209
  - occipital white lock in, 209-210
  - treatment of, 209
  - with deafness, 213
  - with neurologic impairment, 210
- Piercing, ear, tips for, 663
- Pigmentary disorders, in black patients, 271-281
- hyperpigmentation, 273, 275-278, 355, 358-359
    - hydroquinone-induced ochronosis, 276-278
    - mongolian spots, 273, 275
    - postinflammatory, 275-276
    - transient neonatal pustular melanosis, 276
  - hypopigmentation, 278-280, 354-355
    - albinism, 278-279
    - hypopigmented sarcoidosis, 279-280
    - idiopathic guttate hypomelanosis, 278
    - postinflammatory, 278
    - vittigo, 279
  - nuances of pigmentation, 271-273
  - therapy for, 617-618
- Pigmentation, integumental. *See Integumental pigmentation.*
- Pinta, in black patients, 485
- Pityriasis alba, in black children, 466-467
- Pityriasis lichenoides, therapeutic pearl for, 659
- Pityriasis lichenoides chronica, in black children, 465
- Pityriasis rosea, in black patients, 359-359
- Pityriasis rotunda, in black patients, 360
- Pityriasis rubra pilaris, therapy for, 619
- Pityriasis versicolor, ketoconazole for, 631
- Plasma, viscosity of, and pentoxifylline therapy, 593
- Plasmapheresis, for lupus erythematosus, 614
- Platelets, and pentoxifylline therapy, 591-593
- Polymorphic light eruption, in black patients, 374
- PUVA and UVB for, 633-634
  - therapy for, 613, 655
- Polyostotic fibrous dysplasia, pigmentary abnormalities in, 201
- Pomades, use of, by black patients, 491
- and acne, 365
  - and allergic reactions, 365
  - and alopecia, 388
- Porphyrias, in black patients, 373
- Prausnitz-Kustner tests, to diagnose rubber contact urticaria, 50
- Prednisolone, for herpesvirus disorders, 610
- Pressure sores, air-fluidized beds for, 636-637
- Primin, physicochemical methods to detect, 100-101
- Pringle's disease, pigmentary abnormalities in, 198-199
- Printing industry, dermatitis in. *See Occupational dermatoses.*
- Proquazone, for lymphocytic infiltration of skin, 634
- Pruritus, therapeutic pearls for, 659
- Pseudofolliculitis barbae, and related disorders, in black patients, 394, 407-412
- clinical features of, 408
  - dermatitis papillaris capillitii, 410-411, 478-479
  - in women, 410
  - treatment of, 408-410
- Pseudotumor cerebri, retinoids and, 545-546
- Psoralen, and hyperpigmentation, 333
- and ultraviolet light (PUVA), for chronic hand dermatitis, 635
  - for hypopigmentation, in black patients, 355
  - for nonatopic dermatitis, 613
  - for pityriasis lichenoides chronica, in black children, 465
  - for polymorphic light eruption, 633-634
  - for vitiligo, 235-236
  - in idiopathic guttate hypomelanosis, 242
  - plus etretinate, for psoriasis, 640

- Psoralen (*Continued*)  
 topical, for vitiligo, in black patients, 430-431
- Psoriasis, and occupational skin diseases, 11  
 clobetasol propionate for, 643-644  
 cyclosporine for, 577-579  
 etretin for, 639-640  
 etretinate for, 540  
 in black adults, 394  
 in black children, 465-466  
 interferons for, 573  
 methotrexate for, and liver damage, screening for, 641-642  
 of nails, occupational, 32-33  
 PUVA and etretinate for, 640  
 therapy for, 618-619, 659-661
- Psychogenic illness, epidemic, in office workers, 75
- Purpura, senile, therapeutic pearl for, 661
- Pyoderma, malignant, clofazimine for, 582  
 therapy for, 612
- Pyoderma gangrenosum, clofazimine for, 582  
 cyclosporine for, 580  
 pentoxifylline for, 600, 602  
 therapeutic pearl for, 661
- Quinolones, for dermatologic conditions, 514-515  
 adverse reactions to, 515  
 available drugs and their properties, 514-515  
 structure and actions of, 514
- Radiation therapy, for keloids, in black patients, 421
- Radioallergosorbent tests, to diagnose rubber contact urticaria, 50
- Radovan tissue expander, for keloids, in black patients, 381, 383
- Raynaud's phenomenon, nifedipine for, 632-633  
 pentoxifylline for, 598  
 therapy for, 614
- Raynaud's syndrome, therapeutic pearl for, 661-662
- Red blood cells, and pentoxifylline therapy, 589-590
- Retinoids, for dermatologic conditions, 539-552  
 efficacy of systemic retinoids, 539-541  
 acitretin, 541  
 arotinoid ethyl ester, 541  
 etretinate, 540-541  
 isotretinoin, 539-540  
 systemic toxicity of, 541-548  
 lipid abnormalities, 546-547  
 liver, 546  
 mucocutaneous, 541-543  
 musculoskeletal, 544-545  
 neurologic, 545-546  
 ocular, 543-544  
 teratogenicity, 547-548  
 for pityriasis rubra pilaris, 619
- Retinopathy, diabetic, pentoxifylline for, 596
- Retinostriate projections, in albinism, 222
- Rhinoplasty, in black patients, 383-384
- Rhus dermatitis, therapeutic pearls for, 652-653
- Ribavirin, for dermatologic conditions, 526-527
- Rifampin, for dermatologic conditions, 511-513
- Rimantadine, for dermatologic conditions, 525-526
- Ringworm, of scalp, in black patients, 480-482
- Ritodrine, for bullous pemphigoid, 615
- Rocky Mountain spotted fever, in black children, 461-462
- Rosacea, therapy for, 617
- Rubber, manufacture of, dermatitis in. See *Occupational dermatoses*.
- Rubber gloves, contact urticaria from. See *Urticaria*.  
 to protect hands, against occupational dermatoses, 107-113, 115-119  
 allergic contact dermatitis, 118  
 choice for chemical hazards, 108-109  
 choice for mechanical and physical hazards, 110  
 exposure to systemic toxins, 118  
 glove materials, 107-108  
 irritant contact dermatitis, 117-118  
 practical application of data on, 116-117  
 problems and their prevention in, 110-113  
 properties of gloves, 115-116
- Sarcoidosis, in black patients, 279-280, 360
- Scabies, in black children, 462  
 therapy for, 612, 662
- Scalp. See also *Alopecia*; *Hair*.  
 disorders of, in black patients, 391-394  
 ringworm, 480-482  
 dissecting cellulitis of, therapeutic pearl for, 650  
 seborrheic dermatitis of, therapeutic pearls for, 653
- Schamberg's disease, therapeutic pearl for, 661
- Scleroderma, pentoxifylline for, 598  
 progressive systemic, blue macules of, 321, 323  
 therapy for, 614
- Sebaceous glands, activity of, in black patients, 349-351  
 sebum production data, 349-350  
 diseases of, therapy for, 616-617  
 structure and function of, in black patients, 346
- Seborrheic dermatitis, in black adults, 394, 460, 653  
 in black children, 460  
 therapy for, 612-613, 653
- Senile purpura, therapeutic pearl for, 661
- Sexually transmitted diseases, in black patients, 443-456  
 chancroid, 452  
 chlamydial infections, 451-452  
 gonorrhea, 450-451  
 granuloma inguinale, 452-453  
 herpes genitalis, 453-454  
 human immunodeficiency virus infections, 435, 454-455  
 human papillomavirus infections, 453  
 lymphogranuloma venereum, 452  
 syphilis, 443, 450
- Sézary syndrome, cyclosporine for, 579
- Shagreen patches, in tuberous sclerosis, 199
- Shaving, problems of, therapeutic pearls for, 654
- Sick-building syndrome, in office workers, 75-76
- Sickle-cell anemia, and alopecia, in black patients, 393  
 cutaneous signs of, in black children, 469
- Skeletal muscle damage, etretinate and, 641
- Skeletal toxicity, etretinate and, relation between, 640-641
- Skin, infections of. See *Cutaneous infections*.  
 lymphocytic infiltration of, proquazone for, 634  
 structure and function of, in black patients. See *Black patients*.  
 ulcers of, therapy for, 620
- Skin cancer, cryosurgery for, sensory loss after, 631-632  
 in black patients, 397-405  
 basal cell carcinoma, 371, 374, 392-393, 398-399  
 Bowen's disease, 402  
 dermatofibrosarcoma protuberans, 403

- Kaposi's sarcoma, 402-403, 440, 454  
 malignant melanoma, 371, 374, 401-402  
 mycosis fungoides, 403  
 squamous cell carcinoma, 399, 401
- Skin tags, therapeutic pearl for, 664
- Skin tests, to diagnose rubber contact urticaria, 49-50
- Skin types, and occupational skin diseases, 9-10
- Sodium lauryl sulfate, susceptibility of black skin to, 367
- Solar urticaria, in black patients, 374
- Spectrometry, to detect contact allergens, 103
- Spectrophotometry, to detect contact allergens, 103
- Spectroscopy, to detect contact allergens, 103
- Spirolactone, for acne, 617  
   for hirsutism, 616
- Spot test, to detect pruritus, 100
- Squamous cell carcinoma, therapeutic pearls for, 664
- Steroids, for keloids, in black patients, 420  
   systemic, for postherpetic neuralgia, 628
- Strabismus, in albinism, 222
- Surgery, excisional, tips for, 663
- Sweat glands, diseases of, therapy for, 616-617  
   eccrine, structure and function of, in black patients, 345
- Sweating, and occupational skin diseases, 10
- Sycosis barbae, in black patients, 477
- Syphilis, in black patients, annular secondary, 360  
   clinical features of, 443, 450  
   endemic, 485-486
- Telangiectases, therapy for, 622
- Teratogenicity, of etretinate, 554-555  
   of retinoids, 547-548
- Tetracyclines, and hyperpigmentation, 332  
   for bullous pemphigoid, 615  
   for dermatologic conditions, 503-506  
     adverse reactions to, 506  
     available drugs and their properties, 503-506  
     structure and actions of, 503
- Thalidomide, for lupus erythematosus, 614
- Tinea capitis, in black patients, 480-482
- Tinea versicolor, in black patients, 479-480  
   therapy for, 612
- Tioconazole, griseofulvin plus, for onychomycosis, 630-631
- Toxic epidermal necrolysis, therapy for, 616
- Toxins, occupational, sources of information on, 17-18  
   systemic, protective gloves for, 118
- Trauma, and occupational skin diseases, 9  
   of oral melanomas, 286-287  
   of nails, occupational, 29, 32
- Tretinoin, for keloids, in black patients, 421-422  
   plus 5-fluorouracil, for actinic keratoses, 631
- Triamcinolone, and exchange grafts, in idiopathic guttate hypomelanosis, 242-243  
   for keloids, in black patients, 420
- Trichloroacetic acid, for postinflammatory hyperpigmentation, 191
- Trichoclasia, in black patients, 391
- Trichonodosis, in black patients, 391
- Trichorrhexis nodosa, in black patients, 391
- Trimethoprim-sulfamethoxazole, for dermatologic conditions, 509-511  
   adverse reactions to, 511  
   properties of, 510-511  
   structure and actions of, 509-510
- Triparanol, and hair color changes, 300
- Trophic ulcers, pentoxifylline for, 595-596
- Tuberculosis, of skin, in black patients, 483
- Tuberous sclerosis, pigmentary abnormalities in, 198-199
- Ulcerative lesions, in black patients, 360-361
- Ulcers, chronic, of legs, ultrasonography for, 636  
   decubitus, therapeutic pearl for, 664  
   of legs, pentoxifylline for, 600, 664  
   rheumatoid, therapy for, 614  
   sickle-cell, in black children, 469  
   skin, therapy for, 620  
   stasis, therapeutic pearls for, 664-665  
   therapeutic pearls for, 664-665  
   trophic, pentoxifylline for, 595-596  
   tropical, in black patients, 477-478
- Ultrasonography, for chronic leg ulcers, 636
- Ultraviolet radiation, reactions to, in black patients. *See Photosensitivity reactions.*  
   response of melanocytes to, 176
- Urticaria, chlorpheniramine plus cimetidine for, 634  
   contact, from rubber gloves, 47-51  
     diagnosis of, 49-50  
     frequency of, 47-48  
     predisposing factors and prophylaxis in, 50-51  
     symptoms of, 48-49  
   papular, in black children, 464  
   solar, in black patients, 374  
   therapy for, 613, 665
- Urticaria pigmentosa, and postinflammatory hyperpigmentation, 189  
   in black children, 464-465
- Valproic acid, and hair color changes, 300
- Varicella-zoster, acyclovir for, 529
- Vasculitis, leukocytoclastic, therapy for, 614  
   pentoxifylline for, 600
- Vesiculobullous lesions, in black patients, 360
- Vidarabine, for dermatologic conditions, 524
- Visual acuity, in albinism, 221
- Visual display terminals, and skin diseases. *See Occupational dermatoses, in office.*
- Vitamin D3, response of melanoma cells to, 179-180
- Vitiligo, 229-236  
   and diminished hypersensitivity response, 234  
   and melanoma, 234  
   animal models of, 230-231  
   clinical features of, 231-232  
   clobetasol propionate for, 645  
   clofazimine for, 582  
   differential diagnosis of, 232  
   disorders associated with, 233-234  
   etiology of, 229-230  
   in black patients, 279, 425-434  
   classification of, 427  
   clinical features of, 426-427  
   depigmentation in, 431-433  
   differential diagnosis of, 429  
   diseases associated with, 427-428  
   etiology and pathogenesis of, 428-429  
   histology of, 429  
   treatment of, 429-431  
   melanocytes and, 186  
   ocular abnormalities in, 233  
   pathology of, 234  
   treatment of, 235-236, 617, 666

- Vogt-Koyanagi-Harada syndrome, 236-238  
  clinical features of, 236-237  
  etiology of, 237-238
- Voigt's lines, in hyperpigmentation, in black patients, 355, 358
- Volar skin, macules of, 290, 292
- Vulva, melanosis of, 287, 290
- Waardenburg's syndrome, and piebaldism, with Hirschsprung's disease, 212-213  
  depigmentation in, 210-212
- Warfarin, interaction of, with pentoxifylline, 593-594
- Warts, extensive, in children, etretinate for, 639  
  genital, in black patients, 453  
  therapeutic pearls for, 666-667
- White blood cells, and pentoxifylline therapy, 590-591
- Woolf's syndrome, depigmentation in, 213
- Work, dermatoses caused by. See *Occupational dermatoses*.
- Workers' compensation insurance and laws, for occupational dermatoses, 122, 123
- Xanthomata, eruptive, pentoxifylline for, 596, 598
- Xeroderma pigmentosum, and familial melanoma, laboratory studies of, 261-262  
  in black patients, 374
- Yaws, in black patients, 484-485
- Zephiran soaks, for hydrofluoric acid burns, 71
- Zidovudine, for AIDS, 630  
  for dermatologic conditions, 530-532
- Zinc, for acrodermatitis enteropathica, 619
- Zinsser-Cole-Engman syndrome, pigmentary abnormalities in, 196-197

